Researchers at Uppsala University present the development of the CVD-21 tool, a decision-support instrument for cardiovascular disease (CVD) treatment.
The instrument’s development involved analyzing 368 proteins in blood samples from over 10,000 patients in international studies on new CVD and atrial fibrillation treatments. The researchers identified 21 circulating proteins (the CVD-21 panel) from these analyses that serve as biomarkers. Researchers then evaluated this panel using blood samples and clinical information from 4,224 patients with chronic coronary disease.
Regarding risk assessment for cardiovascular complications, the CVD-21 tool, especially when combined with the protein troponin T, showed comparability with models using previously known risk markers for CVD. Additionally, the instrument helped identify nine new biomarkers with predictive significance for various cardiovascular complications, like myocardial infarction and heart failure. Significantly, the study identified several crucial prognostic biomarkers, including MMP-12, U-PAR, REN, VEGF-D, FGF-23, TFF3, ADM, and SCF, underscoring their potential in enhancing prognostic capabilities beyond established markers.
Ref:Siegbahn, A., Eriksson, N., Assarsson, E., Lundberg, M., Ballagi, A., Held, C., Stewart, R. A., White, H. D., Åberg, M., & Wallentin, L. (2023). Development and validation of a quantitative proximity extension assay instrument with 21 proteins associated with cardiovascular risk (CVD-21). PLOS ONE, 18(11). https://doi.org/10.1371/journal.pone.0293465